How Biomarkers Are Transforming Disease Detection, Treatment Selection, and Drug Development

How Biomarkers Are Transforming Disease Detection, Treatment Selection, and Drug Development

Biomarkers have become central to modern medicine. Measurements once used mainly to confirm a diagnosis can now help identify disease risk, distinguish biological subtypes, select treatments, monitor response, and evaluate experimental drugs.

This growing role reflects advances in molecular biology, imaging, laboratory automation, and data analysis. Researchers can measure genes, proteins, metabolites, immune activity, tissue characteristics, and physiological signals in greater detail than before. Yet the value of a biomarker does not depend on technological sophistication alone. It depends on whether the measurement is analytically reliable, clinically meaningful, and useful for a specific decision.

What Is a Biomarker?

A biomarker is a defined biological characteristic measured as an indicator of a normal process, a disease process, or a response to an intervention. Biomarkers can be obtained from blood, urine, saliva, cerebrospinal fluid, tissue, medical imaging, physiological monitoring, or other sources.

Familiar examples include:

• Blood glucose and glycated hemoglobin, or HbA1c, in diabetes
• Cardiac troponin in suspected injury to heart muscle
• Blood pressure as an indicator of cardiovascular physiology and risk
• HER2 expression in some breast and gastric cancers
• EGFR mutations in certain lung cancers
• Viral genetic material detected by molecular tests
• Imaging findings such as tumor size or amyloid deposition
• Circulating tumor DNA released into the bloodstream by cancer cells

A biomarker is not necessarily a diagnosis. Elevated troponin, for example, indicates injury to heart muscle but does not by itself establish the cause. Similarly, a genetic variant may alter disease risk without determining whether or when disease will develop.

The clinical meaning of any result therefore depends on context, including symptoms, medical history, prevalence of disease, test performance, specimen quality, and the decision the test is intended to support.

Major Categories of Biomarkers

Biomarkers are often classified according to their intended use.

These categories can overlap. A single biomarker may be diagnostic in one setting, prognostic in another, and useful for monitoring in a third. Its role must therefore be defined rather than assumed.

Improving Disease Detection

Detecting biological change before obvious symptoms

Many diseases begin at the molecular or cellular level before they produce noticeable symptoms or structural changes. Biomarkers can sometimes identify these early changes, creating an opportunity for earlier investigation or intervention.

Examples include molecular tests that detect infectious organisms, blood markers of organ injury, and screening tests designed to identify precancerous or malignant changes. In neurology, combinations of imaging, cerebrospinal fluid measurements, and increasingly blood-based markers can provide evidence of pathological processes associated with neurodegenerative disease.

Earlier detection is valuable only when the test performs adequately and when acting on the result improves outcomes. A highly sensitive test may identify subtle abnormalities, but it can also detect changes that would never progress to clinically significant disease. This can lead to false alarms, overdiagnosis, invasive follow-up procedures, and unnecessary treatment.

Combining multiple signals

Many disorders cannot be represented by one biological measurement. Researchers are therefore developing multimarker panels that combine several proteins, genetic alterations, metabolites, imaging features, or clinical variables.

A panel may distinguish disease from non-disease more accurately than any single marker. However, adding measurements does not automatically improve a test. Complex models require careful validation because they can fit the data on which they were developed while performing poorly in new populations.

The most useful panels are tested in independent groups that reflect the people and clinical settings in which the test will be used.

Liquid biopsy

Liquid biopsy refers to the analysis of tumor-derived or other disease-related material in body fluids, most commonly blood. In cancer, this may include circulating tumor DNA, tumor cells, RNA, proteins, or extracellular vesicles.

Potential applications include:

• Identifying actionable tumor mutations
• Monitoring response to treatment
• Detecting emerging resistance mechanisms
• Looking for residual disease after treatment
• Supporting cancer detection in selected settings

Liquid biopsy can reduce reliance on invasive tissue sampling and may capture genetic material from multiple tumor sites. Its limitations include low concentrations of tumor-derived material, particularly in early or low-volume disease, and difficulty determining the tissue of origin. Non-cancerous processes can also produce genetic findings that complicate interpretation.

Tissue biopsy therefore remains important in many clinical situations because it provides information about cell structure, tumor type, and the surrounding tissue environment.

Matching Treatment to Disease Biology

The traditional model of treatment often classifies patients primarily by the organ affected and the appearance of disease under a microscope. Biomarkers add a molecular layer, revealing that conditions with similar clinical features may be driven by different biological mechanisms.

Predictive biomarkers and targeted therapies

Predictive biomarkers estimate whether a treatment is more likely to help—or sometimes harm—a particular patient group. They are especially prominent in oncology.

For example:

• HER2 overexpression or amplification can identify tumors that may respond to HER2-directed therapies.
• Certain EGFR mutations in non-small cell lung cancer can indicate sensitivity to EGFR-targeted drugs.
• Defects in specific DNA repair pathways can influence response to selected therapies.
• Some immune-related biomarkers can help estimate the likelihood of response to immune checkpoint inhibitors.

These relationships are rarely absolute. A biomarker-positive tumor may fail to respond because other molecular pathways sustain its growth. A biomarker-negative patient may occasionally benefit because current tests do not capture every relevant mechanism.

Treatment selection therefore depends on the totality of evidence rather than a single laboratory value.

Companion and complementary diagnostics

Some drugs are developed alongside tests that identify patients for whom the therapy is considered appropriate. These companion diagnostics can be essential for safe and effective use. They may determine whether a drug is prescribed, whether an alternative is preferable, or whether additional monitoring is needed.

Complementary diagnostics provide clinically relevant information without being strictly required for treatment. The distinction affects regulatory review, laboratory implementation, and prescribing decisions.

A test and a drug may also evolve separately. New evidence can broaden or narrow the biomarker-defined population, and different testing platforms may not always classify patients identically.

Pharmacogenomic biomarkers

Pharmacogenomics examines how inherited genetic differences affect drug metabolism, transport, targets, and toxicity. Some variants can help explain why a standard dose leads to inadequate exposure in one person but excessive exposure in another.

Where the relationship is well validated, pharmacogenomic testing may support:

• Selection among alternative drugs
• Dose adjustment
• Avoidance of serious adverse reactions
• Interpretation of an unexpected treatment response

The usefulness of a variant depends on the drug, the strength of evidence, the availability of alternatives, and other clinical factors such as age, organ function, interacting medications, and ancestry-related variation.

Monitoring Response and Resistance

A biomarker measured repeatedly can show whether disease activity is rising, falling, or remaining stable. This may provide information sooner than symptoms or conventional imaging.

Examples include viral load in infectious disease, molecular markers in certain blood cancers, and biochemical markers used to monitor endocrine or metabolic conditions.

In cancer, serial analysis of circulating tumor DNA may reveal declining tumor burden during effective therapy or the emergence of mutations associated with resistance. These findings are promising and already useful in selected contexts, but their clinical significance varies by cancer type, disease stage, assay, and treatment.

Monitoring also raises a practical question: does acting on an earlier biomarker change improve outcomes? Detecting resistance sooner is not beneficial by itself unless there is a validated interpretation and an effective alternative strategy.

Changing the Drug Development Process

Biomarkers influence nearly every stage of drug development, from discovery to post-approval monitoring.

Identifying and validating targets

Genetic and molecular evidence can connect a biological pathway with disease. If naturally occurring variation in a gene is associated with altered disease risk or severity, that observation may support the gene or its protein product as a therapeutic target.

Such evidence can strengthen a target hypothesis, but it does not guarantee that a drug acting on the target will be effective or safe. Human biology is interconnected, and the consequences of lifelong genetic variation may differ from those of short-term pharmacological intervention.

Demonstrating target engagement

Early clinical trials need to establish more than whether a candidate drug can be administered safely. Researchers also want to know whether it reaches the relevant tissue and affects its intended target.

Pharmacodynamic biomarkers can show:

• Whether the drug interacts with its target
• Whether a downstream biological pathway changes
• How the effect varies with dose
• How long the effect lasts
• Whether biological activity is associated with clinical response

This information can prevent continued investment in a drug that does not produce the intended biological effect. It can also help select doses for later trials.

Enriching clinical trials

Biomarkers can be used to enroll participants whose disease is more likely to respond to an experimental treatment. This is known as biomarker enrichment.

An enriched trial may detect a treatment effect more clearly because it includes a biologically defined population. It can also spare biomarker-negative participants from exposure to an ineffective drug.

However, enrichment has trade-offs. A narrowly selected trial may make it difficult to determine whether the treatment also benefits patients outside the biomarker-defined group. Recruitment can be slower when only a small proportion of screened participants qualify, and access to high-quality testing may affect who can enroll.

Stratifying heterogeneous diseases

In other trials, biomarkers are used to divide participants into subgroups rather than exclude them. This allows investigators to examine whether treatment effects differ according to biological subtype.

Preplanned subgroup analysis is more reliable than searching for patterns after a trial is complete. Post hoc findings can generate useful hypotheses, but they require confirmation because repeated comparisons increase the chance of misleading results.

Biomarkers as surrogate endpoints

A surrogate endpoint is a biomarker intended to substitute for a clinical outcome such as survival, symptom improvement, or prevention of disability. Surrogates can shorten trials when clinical outcomes take years to occur.

A treatment-induced change in a biomarker is not automatically evidence of clinical benefit. For a surrogate to be dependable, it must capture the relevant effect of treatment on the outcome. Some biomarkers accurately reflect disease activity yet fail to predict whether an intervention makes patients feel better, function better, or live longer.

Regulatory decisions may sometimes rely on surrogate endpoints when the evidence and clinical context support that approach. Continued studies can be necessary to confirm the anticipated benefit.

What Makes a Biomarker Clinically Useful?

A biomarker must pass several distinct tests.

Analytical validity

Analytical validity concerns whether the assay measures the biomarker accurately and reproducibly. Important questions include:

• Does the test detect the intended substance or feature?
• How precise are repeated measurements?
• What is the limit of detection?
• Do specimen collection, storage, or transport affect the result?
• Do different laboratories or platforms produce comparable findings?
• Can medications, inflammation, or unrelated biological factors interfere?

Even a clinically meaningful biomarker has limited value if the assay is unreliable.

Clinical validity

Clinical validity describes how well the biomarker is associated with the condition or outcome of interest. Measures such as sensitivity, specificity, and predictive value are relevant, but they must be interpreted in the intended population.

Predictive values depend partly on how common the condition is in the tested group. A result that performs well in a specialist clinic may be much less informative in broad population screening.

Clinical utility

Clinical utility asks whether using the biomarker leads to a better decision or outcome. A test may be analytically accurate and strongly associated with disease but still offer little practical value if it does not change management, duplicates existing information, or creates more harm than benefit.

Utility can include improved health outcomes, fewer invasive procedures, reduced exposure to ineffective therapies, better safety monitoring, or more efficient use of healthcare resources.

Persistent Challenges

Biological variation

Biomarker levels can vary with age, sex, ancestry, diet, exercise, pregnancy, time of day, kidney or liver function, and coexisting illness. Tumors and other diseases can also vary across tissue sites and over time.

A single sample may therefore provide an incomplete snapshot. Longitudinal measurement can help, but only when meaningful change can be distinguished from normal biological and analytical variation.

Population representation

Biomarkers developed in unrepresentative populations may perform less well in other groups. Genetic variation, environmental exposures, disease prevalence, and access to care can all affect test performance.

Representative study design is consequently part of scientific validity, not only an equity consideration. Validation should include the populations and settings in which a test is expected to be used.

Standardization

Different laboratories may use different antibodies, sequencing methods, imaging protocols, software, thresholds, or reference ranges. Without standardization, a patient can be classified differently depending on the platform.

Reference materials, external quality assessment, transparent algorithms, and comparison studies are important for ensuring that results are transferable.

Data interpretation

Modern assays can produce thousands or millions of measurements. Distinguishing causal biology from correlation is difficult, especially when datasets contain hidden biases or when models are trained on small samples.

Artificial intelligence may help identify complex biomarker patterns, particularly in imaging and multi-omics data. Its performance still depends on data quality, external validation, calibration, and appropriate monitoring after deployment. A complex model should not be considered clinically superior simply because its internal workings are less transparent.

Cost and access

Biomarker-guided medicine can reduce unnecessary treatment, but testing also adds costs and infrastructure requirements. Tissue acquisition, sequencing, specialized imaging, interpretation, and repeat testing may not be widely available.

A biomarker can widen disparities if access to the test determines access to an effective therapy. Clinical implementation must therefore consider laboratory capacity, turnaround time, reimbursement, and the availability of treatment after testing.

The Emerging Role of Multi-Omics and Digital Biomarkers

Researchers increasingly combine information from genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome studies, and medical imaging. These “multi-omics” approaches aim to describe disease as a network of interacting biological changes rather than a single abnormality.

This strategy may improve disease classification and reveal therapeutic targets, but it also increases statistical and operational complexity. Large, carefully characterized datasets are needed to avoid models that appear accurate during development but fail in routine care.

Digital biomarkers are another expanding area. Wearable sensors and connected devices can measure features such as heart rhythm, movement, sleep patterns, respiratory function, or speech. Continuous or frequent measurement may capture changes missed during occasional clinic visits.

At present, the maturity of digital biomarkers varies widely. Device accuracy, adherence, algorithm changes, missing data, privacy, and the clinical meaning of detected changes all require careful evaluation.

A More Precise—but Not Perfect—Model of Medicine

The clearest impact of biomarkers is a shift from classifying disease mainly by symptoms and anatomy toward classifying it by underlying biology. This shift is already established in parts of oncology, infectious disease, cardiology, endocrinology, and inherited disorders.

The broader interpretation is more cautious. Biomarkers are tools for reducing uncertainty, not eliminating it. Their value comes from linking a reliable measurement to a meaningful action. More data do not necessarily produce better care, and earlier detection does not always improve outcomes.

The most consequential biomarkers will be those that do more than identify biological differences. They will demonstrate, through rigorous validation, that those differences can guide decisions that improve treatment effectiveness, safety, or disease prevention.